Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-003-2 | CAS number: 130-95-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is not done according to OECD guideline. But it is a well documented study.
Data source
Reference
- Reference Type:
- publication
- Title:
- Toxicity studies with quinine hydrochloride.
- Author:
- Colley, J. C., Edwards, J. A., Heywood, R. and Purser, D.
- Year:
- 1 989
- Bibliographic source:
- Toxicology. 54:219-226
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- First 13-week rat study:Quinine hydrochloride admixed with the diet was fed to 6 groups of 20 male and 20 female Sprague-Dawley rats at dosage levels of 0, 1, 10, 40, 100 or 200 mg/kg per day. The diet used was Spratt's Laboratory Animal Diet No. 2. Treatment was for 13 weeks with 5 males and 5 females from each group maintained on untreated diet for a further 6-week withdrawal period. The rats were housed in suspended metal cages in groups of 5. The room temperature was maintained at 20 +- 2°C and the relative humidity was 50% (+- 5%). A 12-h light/dark schedule was maintained. Clinical signs and food and water consumption were monitored throughout the study. Body weight was determined weekly. Ophthalmoscopic examinations were carried out after 4 and 12 weeks of compound administration, with haematological and biochemical examinations at the same time intervals. The examinations comprised estimations of packed cell volume, haemoglobin, erythrocyte count, total and differential leukocyte count, platelet count and thrombotest, plasma urea, glucose, total protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, sodium, potassium, chloride, calcium, inorganic phosphorus, creatinine and cholesterol. Post-mortem examinations included weighing of adrenals, brain, heart, kidney, liver, thyroid, pituitary, spleen, testes or ovaries and uterus and a wide range of tissues was prepared for routine histological examination.Second 13-week rat study:A second 13-week study was conducted in Sprague-Dawley rats in order to define more accurately the no-effect level. In this study 4 groups of 20 male and 20 female rats received quinine hydrochloride by dietary admixture at dose levels of 0, 60, 85 or 120 mg/kg per day. Treatment was for 13 weeks with 5 males and 5 females of each group maintained on untreated diet for a further 6 week withdrawal period. The animal management was as for the first studyOtotoxicity study:An assessment of possible ototoxic effects was also made in Sprague-Dawley rats following a 13-week treatment period at dietary intakes of 0, 85 and 200 mg/kg per day. Investigations of hearing thresholds were made using the pre-stimulus startle test method and electrocochleography.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Automatically generated during migration to IUCLID 6, no data available
- IUPAC Name:
- Automatically generated during migration to IUCLID 6, no data available
- Test material form:
- not specified
- Details on test material:
- - Name of test material (as cited in study report): Quinine hydrochloride
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Housing: metal cages in groups of 5- Diet (e.g. ad libitum): The diet used was Spratt's Laboratory Animal Diet No. 2.ENVIRONMENTAL CONDITIONS- Temperature (°C): 20 +- 2°C- Humidity (%): 50% (+- 5%)- Photoperiod (hrs dark / hrs light): 12-h light/dark schedule
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- First 13-week rat study: dosage levels of 0, 1, 10, 40, 100 or 200 mg/kg per daySecond 13-week rat study: dose levels of 0, 60, 85 or 120 mg/kg per dayOtotoxicity study: 0, 85 and 200 mg/kg per day
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:0, 1, 10, 40, 100 or 200 mg/kg per dayBasis:nominal in diet
- Remarks:
- Doses / Concentrations:0, 60, 85 or 120 mg/kg per dayBasis:nominal in diet
- Remarks:
- Doses / Concentrations:0, 85 and 200 mg/kg per dayBasis:nominal in diet
- No. of animals per sex per dose:
- 5 males and 5 females of each concentration
- Control animals:
- yes
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes- Time schedule: throughout the studyBODY WEIGHT: Yes - Time schedule for examinations: weeklyFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes - Time schedule for examinations: throughout the studyWATER CONSUMPTION AND COMPOUND INTAKE: Yes - Time schedule for examinations: throughout the studyOPHTHALMOSCOPIC EXAMINATION: Yes - Time schedule for examinations: after 4 and 12 weeks of compound administrationHAEMATOLOGY: Yes - Time schedule for collection of blood: 4 and 12 weeks of compound administrationBIOCHEMIACL EXAMINATIONS: Yes - Time schedule for collection of blood: 4 and 12 weeks of compound administrationURINALYSIS: Yes
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- no deaths
- Mortality:
- no mortality observed
- Description (incidence):
- no deaths
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- less weight than the controls
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- significantly lower than the control intakes.
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- impairment
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- no effect on water intake
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related findings were observed in the eyes
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- no effect on the haematological parameters
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Higher phosphorus levels were recorded
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- no treatment-related findings
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- not treatment-related effects on the weights of the organs
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- no macroscopic abnormalities
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- In the first 13-week study there were no deaths that could be attributed to treatment or other signs of reaction. Rats receiving 200 or 100 mg/kg per day gained significantly less weight than the controls. Food intakes recorded for rats receiving 200 mg/kg per day were significantly lower than the control intakes. An impairment of efficiency of food utilization was recorded in the rats receiving 200 mg/kg per day. There was no effect on water intake. Laboratory investigations showed slightly elevated plasma urea levels in animals receiving 200 mg/kg per day and in males receiving 100 mg/kg per day. Higher phosphorus levels were recorded in females receiving 40 mg/kg per day and above. The albumin levels recorded for females receiving 200 mg/kg per day were slightly lower than those found in the control animals and lower total protein and globulin levels were recorded at week 12 for females receiving 200 or 100 mg/kg per day. No eye findings were made and hearing function was not impaired. Terminal studies showed no macroscopic abnormalities and organ weight analysis did not show any treatment-related effects on the weights of the organs examined. Morphological change was found in the livers of females receiving 200 or 100 mg/kg per day killed after 13 weeks. This showed as an increased incidence of moderate and/or marked periportal glycogen depletion. A no effect level of 40 mg/kg per day was defined.In the second 13-week study no deaths were recorded. There was suppression of body weight gain in males and females receiving 120 or 85 mg/kg per day and this was associated with lower food consumption. No treatment-related findings were observed in the eyes. There was no effect on the haematological parameters measured. Elevated phosphorus levels were found in female rats receiving 120 mg/kg per day, and these elevated levels tended to persist during the recovery phase Urinalysis did not reveal any treatment-related findings. The terminal studies showed the kidney weights of males receiving 85 or 120 mg/kg per day to be minimally greater than those of the controls. No morphological change was found in the kidneys that could account for this increase in size. No liver pathology was recorded. A no effect level of 60 mg/kg per day was defined. The kidney is identified as a potential target organ at high dose levels. In the ototoxicity study all animals showed good hearing sensitivity across the sound frequency range from 2.5 to 30 kHz and no treatment-related histopathological lesions were detected.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- ca. 40 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: First 13-week rat study:based on decreased body weight and food consumption
- Dose descriptor:
- NOEL
- Effect level:
- ca. 60 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Second 13-week rat study:based on decreased body weight and food consumption
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- For quinine hydrochloride a no effect level of 60 mg/kg per day was defined.
- Executive summary:
The subchronic study (13-week study) on rats, was published by Colley et al., 1989. In the toxicity studies, no deaths were recorded and there were no effects on water intake or urinary output and concentration. The subsequent morphological examinations showed no macroscopic abnormalities and organ weight analysis did not show any treatment-related effects on the weights of the organs examined. Furthermore, there were no effects on the eyes as assessed by indirect ophthalmoscopy and the results of the study let conclude that dietary quinine hydrochloride up to 200 mg/kg per day for 13 weeks did not cause permanent ototoxic effects in rats. There was a significant decrease in body weight after receiving 100 or 200 mg/kg quinine hydrochloride per day. This study allows to define the no effect level of quinine hydrochloride in the Sprague-Dawley rat to be 60 mg/kg per day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.